Author response to: Comment on: Total neoadjuvant therapy versus standard neoadjuvant treatment strategies for the management of locally advanced rectal cancer: network meta-analysis of randomized clinical trials.
Donnelly, Mark; Ryan, Odhrán K; Ryan, Éanna J; Winter, Des C
We welcome the insightful comments from Pedrazzani et al. with regard to our original article1, and congratulate their group on their own recent publication2.
Although the Stockholm III trial3 did meet our predefined inclusion criteria, we have included a repeat of the analysis excluding this trial, and the new data would not have altered our results or conclusions (Appendix S1). We acknowledge that in the interim since our final search date (14 December 2022) that new RCTs of total neoadjuvant therapy (TNT) and other novel strategies for locally advanced rectal cancer have been published, and that these new data are invaluable to any contemporary evaluation of neoadjuvant management strategies.4,5 We also eagerly await the results of ongoing RCTs (NCT02843191, NCT03177382, NCT04518280, NCT05673772, KCT0007169).
↧